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lished and charged with operationalizing the Alzheimer’s Prevention Initiative (API) Genetic Coun-
seling and Disclosure Process for use in the API Generation Program trials. The objective was to
provide consistent information to research participants before and during the APOE counseling
and disclosure session using standardized educational and session materials.
Results: The Genetic Testing, Counseling, and Disclosure Committee created a process consisting of
eight components: requirements of APOE testing and reports, psychological readiness assessment,
determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure
education, APOE counseling and disclosure session materials, APOE counseling and disclosure ses-
sion flow, and assessing APOE disclosure impact.
Discussion: The API Genetic Counseling and Disclosure Process provides a framework for large-
scale disclosure of APOE genotype results to study participants and serves as a model for disclosure
of biomarker results. The process provides education to participants about the meaning and implica-
tion(s) of their APOE results while also incorporating a comprehensive assessment of disclosure
impact. Data assessing participant safety and psychological well-being before and after APOE disclo-
sure are still being collected and will be presented in a future publication.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; APOE; Genetic counseling; Genetic disclosure; Alzheimer’s Prevention Initiative; Genera-tion Program; Clinical trials; Clinical research; Prevention1. Introduction
Alzheimer’s disease (AD) poses a tremendous medical,
economic, and societal burden [1]. In response, the National
Plan to Address Alzheimer’s Disease has set an ambitious
goal of developing treatments to delay onset of AD and
related dementias by 2025 [2]. Given this heightened ur-
gency, at least eight trials of preclinical AD (i.e., prevention)
treatments have been attempted, are ongoing, or are in
various stages of planning [3]. Unlike trials conducted in in-
dividuals in the symptomatic stages of AD, preclinical AD
trials enroll cognitively healthy participants who are at
increased risk for developing clinical symptoms of AD
because of their age, genetics, or the presence of AD-
related biomarkers. Trials that use genes or biomarkers as
eligibility criteria therefore typically require participants to
learn sensitive information along with the associated impli-
cations for their individual risk [4–7].
The Alzheimer’s Prevention Initiative (API), estab-
lished in 2010, is a collaborative research program led
by Banner Alzheimer’s Institute in partnership with other
key organizations working to accelerate the evaluation of
interventions to prevent AD dementia [4,8]. In 2012, API
received a National Institutes of Health (NIH) grant to
help support the Colombia Autosomal Dominant AD Trial
(NCT01998841), the first funded prevention trial of an
investigational disease-modifying treatment in cognitively
unimpaired mutation carriers and noncarriers from the
world’s largest autosomal dominant AD kindred. Because
many kindred members do not want to know their genetic
status and there was no established paradigm for genetic
disclosure in Colombia, this ongoing study includes both
mutation carriers who are randomized to active treatment
or placebo and noncarriers who receive placebo, and it
does not include genetic disclosure [4].In 2013, API received an NIH grant to help support Gen-
eration Study 1 (NCT02565511), the first of two comple-
mentary trials collectively referred to as the Generation
Program and the first funded prevention trial of an investiga-
tional disease-modifying treatment in persons at genetic risk
for late-onset AD [9,10]. Because this ongoing trial is study-
ing cognitively unimpaired 60–75-year-old persons with two
copies of the apolipoprotein E (APOE4) allele, the major
genetic risk factor or AD, a mechanism was needed to
provide APOE4 homozygotes information about their ge-
netic risk before their enrollment. Generation Study 2
(NCT03131453) was subsequently initiated in cognitively
unimpaired APOE4 carriers, including APOE ε4 heterozy-
gotes with a positive amyloid positron emission tomography
(PET) scan and additional APOE4 homozygotes irrespective
of their amyloid PET results [9,10]. Because it is one of the
enrollment criteria, participants in Generation Study 2 must
also receive information about their APOE test results, alone
or in combination with their amyloid PET results. The
design, rationale, and methodology of the API Generation
Program has been published previously [10].
The joint practice guidelines for genetic counseling and
testing for AD from the American College ofMedical Genetics
andGenomics as well as the National Society of Genetic Coun-
selors recommend against APOE genetic susceptibility testing
in clinical practice. The rationale for this recommendation is
the limited clinical utility and prognostic value of testing in or-
dinary clinical use in individual patients and the potential for
unintended psychological and social harms (e.g., distress, ge-
netic discrimination) [11]. However, in a research context,
APOE testing is a useful tool to identify potential participants
for AD prevention studies and is the only context under which
the National Institute on Aging recommends APOE testing
[12]. In cases where APOE testing of cognitively unimpaired
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netics and Genomics as well as National Society of Genetic
Counselors joint practice guidelines recommend counseling
and disclosure be completed with a qualified genetics profes-
sionalwith a protocolmodeled after the genetic testing protocol
for Huntington’s disease (HD) [13], which is based on the In-
ternational Huntington Association and World Federation of
Neurology Research Group on Huntington’s Chorea Guide-
lines, as it is considered bymany to be the gold standard for ge-
netic testing for adult onset conditions [14]. The HD protocol
incorporates multiple in-person visits that include one or two
pretesting genetic counseling sessions incorporating mental
health and neurological assessments, followed by genetic
testing, a return visit for disclosure of results and counseling
support, and finally a follow-up visit or a phone call [13,14].
Available data suggest that APOE disclosure using tradi-
tional genetic counseling and disclosure protocols, such as
those modeled after the HD protocol guidelines, can be con-
ducted safely and effectively [15–19]. Although traditional
models of APOE genetic counseling and disclosure have
been shown to be effective, they are not scalable. To
identify the number of participants with the appropriate
APOE results required by preclinical AD studies, a
substantial number of persons will need to learn their
APOE results. For example, to enroll approximately 3000
individuals into the Generation Program trials, we estimate
that many more thousands of individuals will need to
undergo genetic testing and learn their APOE results.
Previous research studies developed condensed
standardized APOE genetic counseling and disclosure
protocols, providing written educational precounseling
materials in lieu of the traditional in-person educational pre-
test counseling session to reduce trial site and participant
burden. Compared with the traditional model, this
condensed protocol was found to be equivalent in terms of
participants’ understanding and test-related distress and
required significantly less face-to-face clinician time
[20,21]. Although most studies using either traditional or
condensed protocols report no significant increases in
depression or anxiety symptoms among participants
learning their APOE results, it is important to note that these
outcomes have been studied in restricted settings and popu-
lations, with relatively few individuals at the highest risk
level (i.e., APOE4 homozygotes) or those close to the esti-
mated age of symptom onset. These studies typically
involved disclosure provided by expert genetic counselors
to generally well-educated at-risk middle-aged individuals
(based on family history of AD) who volunteered to learn
such information and were screened to confirm psychologi-
cal well-being before counseling and disclosure [15–18,21].
Recognizing the significance and sensitive nature of
disclosing this type of information, as well as the need to
address the scale of APOE genetic counseling and disclosure
required by the Generation Program trials, the API team es-
tablished a multidisciplinary Genetic Testing, Counseling,
and Disclosure (GTCD) Committee to develop an APOEgenetic counseling and disclosure process to responsibly pro-
vide participants with clear and consistent communication of
genetic information in the Generation Program and to serve as
a model for dissemination into clinical practice, complement-
ing processes developed by other large-scale AD prevention
programs for communication of biomarker results [22,23].
This article describes the rationale for, and methods used to
develop the API Genetic Counseling and Disclosure Process,
as well as challenges and future directions.2. Methods
2.1. Process development
The API team recognized early in the planning stages for
the Generation Program the need for special attention and
consultation from qualified experts in the development of a
program-specific APOE genetic counseling and disclosure
process. The GTCD Committee was established to inform
and guide the design of the API Genetic Counseling and
Disclosure Process for use in the Generation Program. It com-
prises physicians, social science researchers, health educators,
legal experts, and genetic counselors, with expertise in AD,
medical ethics, and disclosure of genetic risk factors. At the
start of protocol development, the GTCD Committee met
every 2 weeks by telephone and approximately quarterly in
person. The committee continues to meet monthly by tele-
phone during study implementation. The committee opera-
tionalized eight components comprising the API Genetic
Counseling and Disclosure Process whose core features
include guidelines for APOE testing and reports and providers
of disclosure, standardized education and structured content
of counseling and disclosure sessions, in-clinic assessment
of well-being, assessment of psychological readiness for
disclosure and evaluation of APOE disclosure impact (Fig. 1).
2.2. APOE genetic testing
Some individuals enroll in the Generation Program
already knowing their APOE genotype from prior genetic
testing (e.g., via direct-to-consumer testing); nevertheless,
for quality control and standardization purposes, the API
Genetic Counseling and Disclosure Process requires all par-
ticipants to complete an APOE counseling and disclosure
session. This requirement also ensures all participants have
access to the same information about APOE and the associ-
ated risk for AD, as well as providing all participants an op-
portunity to discuss their results with a provider. All
participants complete APOE testing via the study’s central
laboratory as part of screening regardless of prior testing,
but in cases where a report for previous APOE genotyping
can be obtained and confirmed as completed by an appropri-
ately certified laboratory (per local regulations, e.g., Clinical
Laboratory Improvement Amendments and College of
American Pathologists accreditation), these initial results
may be used for the APOE counseling and disclosure
session.
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Fig. 1. Alzheimer’s Prevention Initiative Genetic Counseling and Disclosure Process components. Abbreviations: APOE, apolipoprotein E; API, Alzheimer’s
Prevention Initiative; AD, Alzheimer’s disease.
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disclosure
To reduce the risk of negative psychological reactions to
disclosure of APOE results, measures to assess psychologi-
cal readiness to receive results are administered by trained
site personnel before the genetic counseling and disclosure
session can proceed. The 15-item version of the Geriatric
Depression Scale (GDS) [24] and the Six-Item Subset of
the State-Trait Anxiety Inventory for Adults (STAI-AD)
[25,26] are used as assessments of psychological readiness
in both Generation Program studies as they are well-
known measures of mood and anxiety with established clin-
ically meaningful defined score ranges. Generation Study 2
adds the electronic version of the Columbia Suicide Severity
Rating Scale (C-SSRS) [27] to assess current and prior life-
time suicidal ideation and behaviors, whereas in Generation
Study 1, this was assessed by clinical judgment before ge-
netic disclosure. However, the C-SSRS is administered to
APOE4 homozygotes in part 2 of Generation Study 1 as
described previously [10].In Generation Study 1, psychological readiness assess-
ment scores above a specified threshold (GDS .6 and
STAI-AD .19) results in automatic exclusion, whereas
scores within flagged ranges require additional investigator
review for inclusion, with special attention to responses on
specific questions (Table 1). Generation Study 2 also uses
GDS and STAI-AD as assessments of psychological readi-
ness, with specified scores requiring additional investigator
review for inclusion (Table 1), but no exclusionary cutoffs
are included for GDS or STAI-AD to allow for increased
flexibility for investigators to use their clinical judgment
when evaluating participants’ psychological readiness.
However, Generation Study 2 adds the electronic version
of the C-SSRS as an additional measure of psychological
readiness, resulting in exclusion of participants who report
active suicidal ideation (with at least some intent to act) in
the past 6 months and/or those reporting suicidal behavior
(not including nonsuicidal self-injurious behavior) in the
past 2 years. If participants are excluded from study partic-
ipation based on suicidality, participant safety and
Table 1
Psychological readiness criteria
Generation Study 1
 Psychological readiness to receive APOE genotype information based on predisclosure rating scales, specifically:
B GDS Short Form total score ,6.
If the score is between 6 and 10 (inclusive), the participant can only be included based on investigator’s judgment
assessing in particular the scores of the questions:
i. Item 3: “Do you feel your life is empty?”
ii. Item 6: “Are you afraid that something bad is going to happen to you?”
iii. Item 12: “Do you feel pretty worthless the way you are now?”
iv. Item 14: “Do you feel your situation is hopeless?”
B Six-Item Subset Inventory of the STAI-AD total score ,17.
- If the score is between 17 and 19 (inclusive), the participant can only be included based on the investigator’s judgment
Generation Study 2
 Lacking psychological readiness to receive APOE genotype/amyloid status results, as assessed based on investigator’s judgment supported
by the predisclosure rating scales:
B GDS Short Form total score . 6
B Six-Item Subset Inventory of the modified STAI-AD total score .17
 C-SSRS exclusion criteria
B Reports active suicidal ideation with at least some intent to act, with or without a specific plan, if this ideation occurred in the past 6 months
B Reports suicidal behavior (not including nonsuicidal self-injurious behavior) if this behavior occurred in the past 2 years before screening
Abbreviations: APOE, apolipoprotein E; GDS, Geriatric Depression Scale; STAI-AD, State-Trait Anxiety Inventory for Adults; C-SSRS, Columbia
Suicide Severity Rating Scale.
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process for referral and follow-up with mental health re-
sources varies by country as does site access to mental health
professionals (e.g., some site investigators are psychiatrists).2.4. Risk estimates
To provide estimates of risk for development of mild
cognitive impairment (MCI) or dementia due to AD tailored
to the Generation Program study population, data from four
large prospective longitudinal studies were analyzed for the
incidence of MCI or dementia among initially cognitively
unimpaired individuals aged 60–75 stratified by APOE ge-
notype. The results from these analyses were published pre-
viously [28]. In brief, 5-year risk estimates by age group
(e.g., 60–64, 65–69) were found to be highly variable in
comparison to lifetime risk estimates (defined as through
age 85); therefore, the API Genetic Counseling and Disclo-
sure Process provides lifetime risk estimates in the corre-
sponding APOE genetic counseling and disclosure
materials [28]. In addition, the AD risk estimates developed
for the Generation Program are lower than those published
previously and used for APOE disclosure in the REVEAL
studies and by direct-to-consumer genetic testing companies
[29,30]. These lower risk estimates supported the decision to
require all Generation Program participants to complete a
genetic counseling and disclosure session, regardless of
prior knowledge of APOE status, to ensure all participants
are provided with these updated population-specific AD
risk estimates.2.5. Genetic counseling and disclosure providers
Multiple strategies are used to address limited site access
to genetic counselors or other genetics-trained professionals.In the United States and Canada, sites can not only use local
providers of genetic counseling and disclosure but also have
access to centralized remote genetics services, where an off-
site genetic counselor completes the APOE counseling and
disclosure session via telephone or videoconference.
Outside the United States and Canada, local providers are
used primarily. Local providers of genetic counseling and
disclosure must be qualified per local laws and regulations
governing genetic counseling and associated licensure re-
quirements of providers. In areas where no regulations exist,
the Sponsors recommend that providers of genetic coun-
seling and disclosure be trained clinical professionals with
an advanced understanding of genetics and experience
with providing potentially sensitive medical results. In cases
of uncertainty, qualifications of the proposed provider are re-
viewed and approved by the Sponsors.
2.6. Predisclosure genetic education materials
To reduce participant burden and address the considerable
number of APOE genetic counseling and disclosure sessions
expected to meet enrollment goals of the Generation Program,
the API Genetic Counseling and Disclosure Process uses a
condensed model that can be completed in a single visit to a
Generation Program study site. To accommodate a condensed
model, we developed self-directed learning materials,
including an Educational Predisclosure Video and Disclosure
Informational Brochure (both accessible to participants before
the genetic counseling and disclosure visit) covering content
typically addressed in a pretesting genetic counseling session.
The Video and Brochure provide a summary of the APOE
gene and its relationship to AD, as well as considerations for
learning one’s APOE genotype for both the participant and
their family (e.g., potential emotional responses, implications
of AD risk for blood relatives). The Video incorporates several
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response to help confirm and reinforce participant understand-
ing. Participants are strongly encouraged to review these mate-
rials in advance of the APOE counseling and disclosure session
to orient and familiarize themselves with the information ad-
dressed during the session. These key points are also included
in the study of informed consent form to ensure participants are
presented with this information before enrolling in the trial.2.7. Genetic counseling and disclosure session materials
Several supportive materials are used in the API Genetic
Counseling and Disclosure Process to help standardize the
APOE counseling and disclosure session. A Genetic Coun-
seling and Disclosure Session Handout and a set of Genetic
Counseling and Disclosure Session Talking Points (Table 2)
help standardize the content of the session. The provider
uses the Handout as a visual aid during the counseling and
disclosure session (participants are provided with a copy
for note taking and to keep) and uses the Talking Points as
a reference guide for the session. The Talking Points are in-
tended to help address the variability of experience andTable 2
Genetic counseling and disclosure session talking points for participants undergo
API Genetic Counseling and Disclosure Process: genetic counseling and disclosu
1. Introduction to session
2. Review purpose of session and confirm the individual’s interest in partici
3. Review family history, with focus on AD/dementia
4. Basic clinical description of AD, MCI, and dementia
5. Impact of APOE on AD risk
a. Cannot definitively predict or rule out development of AD
b. No medical management currently available based on APOE status
c. Review three possible results and associated AD/MCI risk
i. Zero copies (ε3/ε3, ε2/3, ε2/ε2)
ii. One copy (ε3/ε4, ε2/ε4)
iii. Two copies (ε4/ε4)
6. Inheritance of APOE gene; address possible implications for children and
7 Considerations for learning APOE results
a. Psychological impact
b. Familial impact
c. Clinical research impact
8. Review Genetic Information Nondiscrimination Act (pertains to United St
9. Address specific concerns or considerations about learning APOE result
10. State option to either proceed with disclosure of APOE genetic testing res
a. If proceeding with disclosure, talking points 11–16 would follow
b. If postponing, review plan for participant to recontact site when ready to
ending the session
c. If declining disclosure, participant would be given time to address thei
11. Disclosure of APOE result
a. If participant receives genotype containing rare ε3 (ε3r) variant, provid
information in the “Rare APOE ε3r gene variant” slide in the standard
12. Disclosure of AD risk information
a. Provide comparison for other APOE genotypes to provide context
13. Allow participant to ask questions and/or discuss issues of concern or int
14. Address participant’s emotional response to result (if any)
15. Review plan for follow-up phone calls by study coordinator
16. State eligibility for next steps in research participation
Abbreviations: APOE, apolipoprotein E; API, Alzheimer’s Prevention Initiative
*Talking points for participants already aware of their APOE status is availableexpertise providers may have in educating participants in ge-
netics and with disclosing APOE results. The Talking Points
highlight key topics to be addressed during the session but
are not intended to be exhaustive or restrictive.
Participants who enroll in the Generation Program
already knowing their APOE results are required to complete
an APOE counseling and disclosure session as part of the
API Genetic Counseling and Disclosure Process, but a
slightly modified set of talking points are used with these
participants (See Supplementary Table 1). Talking points
for participants already aware of their APOE genotype do
not include review of disclosure implications or confirma-
tion of their desire to learn results (as they are already
known) but add a discussion of the previous disclosure expe-
rience and any impact it had on the participant and their
family.
APOE Risk Estimate Summary Sheets are available for
each possible genotype and provided to participants after
the session to serve as a record of their results and the asso-
ciated risk information reviewed during the session. For pur-
poses of the Generation Program, a Genetic Counseling and
Disclosure Session Manual outlines the entire API Geneticing first time disclosure of their APOE results
re session talking points with individuals receiving first-time* disclosure
pation
siblings
ates only)
ults, postpone disclosure to later date, or decline disclosure of APOE results
proceed with disclosure. Address remaining questions and concerns before
r questions or concerns before ending the session
e education and risk assessment for corresponding ε3 genotype and address
ized APOE risk handout
erest that are of most importance to them after learning result
; AD, Alzheimer’s disease; MCI, mild cognitive impairment.
in the supplemental online information.
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Prepare for Genetic Counseling and 
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the Process were written in American English but were de-
signed to be generally applicable worldwide, often only
requiring translation and/or subtitles. The materials were de-
signed to be edited easily (e.g., made with commonly avail-
able software packages in editable formats) in case
modifications are needed for cultural adaptation. The API
Genetic Counseling and Disclosure Process materials are
available on request at the discretion of the authors.Disclosure Session
- Confirm certified APOE results available
- Verify psychological readiness 
Genetic Counseling and 
Disclosure 
- Using standardized materials and 
provider talking point
- Provider to confirm continued desire to 
learn results prior to disclosure 
Genetic Disclosure Follow-Up
- Consists of assessments administered in 
- Completed regardless of trial eligibility
person or over the telephone
Fig. 2. Alzheimer’s Prevention Initiative Genetic Counseling and Disclo-
sure Process flow. Abbreviation: APOE, apolipoprotein E.2.8. Genetic counseling and disclosure sessions
The APOE counseling and disclosure session begins with
a brief review of the educational content from the Educa-
tional Predisclosure Video and Disclosure Informational
Brochure, as well as a discussion of the participant’s family
history, feelings toward APOE disclosure, and consider-
ations for learning one’s APOE results. Before disclosure
of APOE results and associated risk estimates, the provider
is required to confirm the participants’ continued desire to
learn their APOE results (for people who do not already
know their APOE genotype). After disclosure, with consid-
eration given to the emotional and informational needs of the
participant, the provider also discusses inheritance implica-
tions, degree of risk comparisons, potential risk modifiers,
and offers resources for more information. The Risk Esti-
mate Summary Sheet corresponding with the participant’s
APOE result is given to the participant at the end of the ses-
sion. All genetic counseling and disclosure sessions are
completed with the participant at a study site, even if the
site is using remote genetic services, to ensure study staff
are immediately available if needed. Post-disclosure
follow-up with the participant can be completed by tele-
phone or in person. The materials used in the API Genetic
Counseling and Disclosure Process were designed to be
easily adaptable to local standards and regulations. Fig. 2
presents a flowchart summarizing the API Genetic Coun-
seling and Disclosure Process.2.9. Assessing impact of APOE disclosure
Given the limited available data on the outcomes of
APOE disclosure, specifically in the context of clinical trials,
and the desire to demonstrate the utility of the process, the
API Genetic Counseling and Disclosure Process incorpo-
rates follow-up measures to assess the impact of participants
learning their APOE results. Generation Study 1 includes a
robust battery assessing impact of APOE disclosure admin-
istered 2–7 days, 6 weeks, 6 months, and 12 months after
disclosure (Table 3). Assessments included in Generation
Study 1 genetic disclosure follow-up period include mea-
sures of participant psychological well-being, understanding
and retention of information presented throughout the API
Genetic Counseling and Disclosure Process, perceptions of
perceived risk and threat of AD, and assessments of the gen-
eral impact of APOE testing and motivation for learningthese results, as well as participant satisfaction with the ge-
netic services provided, including satisfaction with remote
counseling, when applicable.
In contrast, Generation Study 2, which began recruitment
approximately 18 months after Generation Study 1, includes
an abbreviated battery, with only a 2–7-day follow-up using
the GDS and STAI-AD, because thorough APOE disclosure
follow-up is being completed in an adequately large sample
as part of Generation Study 1. To reduce participant burden,
all postdisclosure follow-up assessments may be adminis-
tered over the phone or in person for both studies. The
schedule of assessments for genetic disclosure follow-up
in both Generation Study 1 and Generation Study 2 is pro-
vided in Table 3. It is important to note that key safety assess-
ments (e.g., assessment of adverse events and serious
adverse events, assessments of suicidality) are completed
in all participants throughout both studies, independent of
APOE disclosure follow-up.
Table 3
Generation Program genetic disclosure follow-up schedule of assessments
Visit timepoint Day 1 (disclosure visit) 2–7 Days 6 Weeks 6 Months 12 Months
Visit number 1 101 102 103 104
Generation Sudy 1
Genetic counseling X
Disclosure of genotype X
Six-Item Subset of the STAI-AD [25,26] X X X X X
GDS [24] X X X X X
Knowledge of genetic disease [31–33] X X X X X
Disease-specific distress (adapted Impact of Events Scale) [34–36] X X X X X
Perceived risk of AD [37,38] X X X X X
Perceived threat about AD [39] X X X X X
Motivation for learning APOE results X
REVEAL IGT-AD [40] X X X X
Satisfaction with remote counseling [41–43] X
Satisfaction with genetic services [44] X
Generation Study 2
Genetic counseling X
Disclosure of genotype X
Six-Item Subset of the STAI-AD [25,26] X X
GDS [24] X X
Abbreviations: STAI-AD, State-Trait Anxiety Inventory for Adults; GDS, Geriatric Depression Scale; AD, Alzheimer’s disease; APOE, apolipoprotein E;
IGT-AD, Impact of Genetic Testing for Alzheimer’s disease.
C.M. Langlois et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 705-7167123. Discussion
At this time, APOE counseling and disclosure are usually
not recommended in the clinical setting because of lack of
clinical utility [11]; however, when disclosure is necessary,
the recommended traditional models of genetic counseling
and disclosure require multiple visits and a substantial
amount of time with a genetics-trained professional
[13,14]. The Generation Program (and potentially other
future preclinical AD trials) requires identification of indi-
viduals at high risk for developing dementia due to AD based
in part on APOE genotype [3,9,10]. Thousands of individ-
uals will need to undergo APOE genetic testing, counseling,
and disclosure as part of the sizable recruitment and
screening funnel required to meet prevention study program
enrollment goals [45]. As such, an alternative to traditional
models of genetic counseling and disclosure is needed to
provide comprehensive standardized counseling and disclo-
sure of APOE results efficiently, safely, and effectively in the
context of AD prevention trials. The API Genetic Coun-
seling and Disclosure Process was designed to meet these
needs for the Generation Program and to serve as a much-
needed framework for future endeavors requiring large-
scale APOE genetic counseling and disclosure with
cognitively healthy older adults.
Enlisting multidisciplinary experts was critical in the
design of the API Genetic Counseling and Disclosure Pro-
cess. Including committee members with wide-ranging areas
of expertise and backgrounds led to the creation of an ethi-
cally sound, practicable, and comprehensive process
strengthened by the wealth of knowledge and insight offered
by the GTCD committee. Numerous factors were taken into
consideration, including how best to provide comprehensivestandardized genetic counseling and disclosure-related in-
formation to participants. In the Generation Program,
APOE counseling and disclosure is completed at sites across
the world by providers with varying levels of relevant
training and experience. To ensure consistency of communi-
cation of information to participants before and during the
APOE counseling and disclosure session, the GTCD com-
mittee developed educational and session materials (e.g.,
Education Predisclosure Video, Genetic Counseling and
Disclosure Session Handout, Genetic Counseling and
Disclosure Session Talking Points) to direct the API Genetic
Counseling and Disclosure Process and support providers of
genetic counseling and disclosure, especially those with
limited experience in delivering APOE results. To provide
applicable estimates of APOE-associated risk of developing
MCI or dementia because of AD for use in the API Genetic
Counseling and Disclosure Process materials, updated life-
time risk estimates tailored to the Generation Program study
population were calculated based on four large longitudinal
studies [28].
It was also necessary to address the logistical consider-
ations of completing a substantial number of APOE coun-
seling and disclosure sessions. To reduce participant
burden and amount of time needed with a provider, the
API Genetic Counseling and Disclosure Process is
completed during one visit to the study site. To facilitate a
condensed model, participants complete precounseling edu-
cation independently and/or remotely via a web-accessible
Education Predisclosure Video and written Disclosure Infor-
mational Brochure instead of the pretest in-person genetic
counseling visit typically included in traditional models of
genetic counseling and disclosure [14]. Also, all
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the phone, further reducing the number of visits to the study
site.
Preclinical AD studies such as the Generation Program are
conducted globally at numerous sites with varying levels of ac-
cess to genetics-trained professionals with varying experience
disclosing APOE results. The API Genetic Counseling and
Disclosure Process was designed to provide a consistent partic-
ipant experience regardless of the genetic counseling and
disclosure provider’s experience level by incorporating stan-
dardizedmaterials, including aGenetic Counseling andDisclo-
sure Session Handout and Genetic Counseling and Disclosure
Session Talking Points to guide the session. In addition, APOE
Risk Estimate Summary Sheets are available for each possible
genotype result and are provided to participants after the ses-
sion to serve as a record of their results and the associated
risk information reviewed during the session.
Another way to improve access to professionals trained
in genetics is the use of remote genetics services. Several
studies in cancer have shown telephone-based delivery of
genetic results to be safe [46–51], and one study has
shown delivery of APOE results by telephone to be
equivalent to in-person sessions on scores of anxiety,
depression, and test-related distress [18]. Currently, only
Generation Program trial sites in the United States and
Canada have access to centralized remote genetics ser-
vices; however, the comparison of telephone-versus video-
conferencing-based remote disclosure is being assessed at
some sites in the United States as an investigator-initiated
ancillary study (NCT02978729) to better understand impli-
cations of remote delivery modality [52]. Data from this
ancillary study are being collected and will be shared in a
future article.
The API Genetic Counseling and Disclosure Process was
also designed to protect and monitor participant safety and
well-being. As in previous research investigating impact of
APOE disclosure, measures verifying psychological well-
being are administered before the genetic counseling and
disclosure session can proceed. Several assessments in-
tended to evaluate psychological readiness to receive
APOE results are administered, and in conjunction with
investigator judgment, are used to determine whether it is
appropriate for the participant to continue with APOE coun-
seling and disclosure. Given the limitations of available
research assessing the impact of APOE disclosure, particu-
larly in the context of clinical trials, the API Genetic Coun-
seling and Disclosure Process includes measures assessing
psychological well-being as well as assessments evaluating
how learning this information affects participants’ under-
standing of, feelings toward, and beliefs about AD. These
outcomes of APOE disclosure are being evaluated across
all sites to inform real-world variation outcomes in a global
trial. These data are being collected, and we look forward to
reporting the results in the future.
The work done to develop the API Genetic Counseling
and Disclosure Process for return of APOE results to cogni-tively normal AD prevention study participants comple-
ments processes developed by the Anti-Amyloid
Treatment in Asymptomatic Alzheimer’s Disease (A4)
Study to disclose amyloid imaging results in the context of
a preclinical AD trial [22] as well efforts from the European
Prevention Alzheimer’s Disease project assessing perspec-
tives related to communication of biomarker-based risk of
AD [23]. These programs, along with our work, will likely
inform future strategies for communicating biomarker-
based AD risk results to optimize outcomes in both the
research and clinical settings.
Although the API Genetic Counseling and Disclosure
Process offers a framework to complete large-scale
APOE genetic counseling and disclosure in the context
of an AD prevention clinical trial, we acknowledge several
limitations. First, the API Genetic Counseling and Disclo-
sure Process has only been implemented in two companion
AD prevention studies of similar design but was designed
to serve as a framework informed by standard genetic
counseling and education principles to provide standard-
ized APOE counseling and disclosure that accounts for
anticipated real-world practice variations. For example,
the API Genetic Counseling and Disclosure Process has
already served as the foundation for the amyloid disclosure
process in Generation Study 2. Second, applicability of the
API Genetic Counseling and Disclosure Process outside a
clinical trial setting is unclear as it has only been imple-
mented as part of the Generation Program and has yet to
be tested in a nonresearch-based clinical setting and popu-
lation. In addition, to implement the API Genetic Coun-
seling and Disclosure Process for another purpose,
several of the materials may need to be updated and modi-
fied as those used in the API Genetic Counseling and
Disclosure Process are tailored to the Generation Program.
Certain materials may also need to be updated as the field’s
understanding of APOE and its associated risk of AD
evolves over time. Third, measures of APOE disclosure
impact included in the Generation Program focus on
participant safety, well-being, understanding of and
thoughts about AD, but other areas of impact warrant
investigation. As such, additional areas of impact are being
assessed as ancillary studies, including whether disclosure
of APOE results is associated with worsening of subjective
and objective cognitive functioning and stigma, as well as
assessing potential differences based on delivery modality
of remote genetic services (i.e., telephone vs. videoconfer-
ence) [52].3.1. Future directions
The API Genetic Counseling and Disclosure Process
provides a novel framework for completing APOE coun-
seling and disclosure in the context of AD prevention tri-
als, such as those in our API studies. The APOE
disclosure impact data we are collecting will help us un-
derstand the risks and benefits of modifying traditional
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for future adaptations of the current disclosure model in
the research and clinical settings. Although comprehen-
sive disclosure outcome data are being collected as part
of the Generation Program and several ancillary studies
are underway, additional areas of APOE disclosure impact
warrant further examination, including evaluation of po-
tential modifications to health and lifestyle behaviors,
changes in financial behaviors, employment, and other
economic factors, as well as potential impact of stigma
and discrimination in response to APOE disclosure. It is
imperative that we better understand the impact of
APOE disclosure as an increasing number of individuals
are learning this information as part of research and other
activities, notably direct to consumer genetic testing [53].
Incorporating additional risk factors and modifiers to
create a more comprehensive and individualized assess-
ment of AD risk is another area warranting further study.
For example, because PET, cerebrospinal fluid, and prom-
ising blood-based biomarker measurements may be used to
screen or select participants in AD prevention studies, it
will help to further optimize our approach to estimate a
person’s AD risk based on a combination of biomarker
and APOE genotype results [3,54]. It will also be beneficial
to understand better the impact of other potential modifiers
(e.g., sex, health conditions) on personalized risk estimates
for developing MCI or dementia because of AD. In addi-
tion, future research may not just rely on the APOE gene
to identify participants at risk for AD but may use poly-
genic risk scores [55]. Better understanding the various
risk factors, how they interact, and implications of various
modifiers could eventually lead to the creation of a person-
alized AD risk calculator similar to the one developed by
the American College of Cardiology and American Heart
Association, which provides a personalized numerical
risk value of developing atherosclerotic cardiovascular dis-
ease based on variety factors [56].4. Conclusion
As the number of AD prevention studies continues to in-
crease, an alternative to traditional genetic counseling and
disclosure models is needed because of the substantial num-
ber of visits and face-to-face clinician time required, which
is not always feasible in the context of a clinical trial. To
address this need, the API Genetic Counseling and Disclo-
sure Process was developed to provide a comprehensive
and standardized alternative process for APOE counseling
and disclosure in the Generation Program and to serve as a
framework for large-scale APOE genetic counseling and
disclosure programs in the future. The APOE disclosure
impact data being collected will be vital in helping to better
understand the risks and benefits of modifying traditional ge-
netic counseling and disclosure models and will likely
inform future adaptations to optimize patient outcomes for
both the research and clinical settings.Acknowledgments
This Generation Program is funded by Novartis Pharma AG,
Basel, Switzerland and Amgen, Thousand Oaks, CA, USA,
in collaboration with the Banner Alzheimer’s Institute
located in Phoenix, AZ, USA. Generation Study 1 is sup-
ported by funding from the National Institute on Aging
(1UF1AG046150), part of the National Institutes of Health,
as well as the Alzheimer’s Association, Fidelity Biosciences
Research Initiative, GHR Foundation, and Banner Alzheim-
er’s Foundation. The authors acknowledge Drs Doris Zallen,
Linda Patrick-Miller, Richard Caselli, Gary Marchant, Ana
Graf, Cristina Lopez Lopez, Kristin Harkins, and Trisha
Walsh. The opinions expressed by Scott Y.H. Kim are his
own and do not represent the views of the NIH, US Depart-
ment of Health and Human Services, or any other part of the
US government.
Authors’ contributions: All authors participated in the study
design, implementation, and/or conduct of the API Genetic
Counseling and Disclosure Process. All authors contributed
to the review of the protocol and approved the final article.
Supplementary Data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.trci.2019.09.013.RESEARCH IN CONTEXT
1. Systematic review: We used sources such as PubMed
to review the literature on genetic counseling and
disclosure, with a focus on disclosure of apolipopro-
tein E (APOE) for risk of Alzheimer’s disease.
2. Interpretation: The Alzheimer’s Prevention Initia-
tive’s Genetic Counseling and Disclosure Process
consists of eight components whose core features
include guidelines for APOE testing requirements
and providers of disclosure, standardized education
and structured content of disclosure sessions, assess-
ment of well-being and psychological readiness for
disclosure, and evaluation of disclosure impact. The
process provides a framework for large-scale
disclosure of APOE genotype results to study par-
ticipants and serves as a model for disclosure of
biomarker results.
3. Future directions: Results from these studies will
help us understand the impact of APOE disclosure
as well as the implications of modifying traditional
counseling and disclosure models and set the stage
for future adaptations of the current model in
research and clinical settings.
C.M. Langlois et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 705-716 715References
[1] Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al.
The worldwide costs of dementia 2015 and comparisons with 2010.
Alzheimers Dement 2017;13:1–7.
[2] National Plan to Address Alzheimer’s Disease: 2018 Update US
Department of Health and Human Services, Office of the Assistant
Secretary for Planning and Evaluation; 2018. Available at: https://
aspe.hhs.gov/system/files/pdf/259581/NatPlan2018.pdf. Accessed
October 23, 2019.
[3] Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug
development pipeline: 2018. Alzheimers Dement (N Y) 2018;
4:195–214.
[4] Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S,
Schneider LS, et al. The Alzheimer’s Prevention Initiative
Autosomal-Dominant Alzheimer’s Disease Trial: a study of crenezu-
mab versus placebo in preclinical PSEN1 E280A mutation carriers
to evaluate efficacy and safety in the treatment of autosomal-
dominant Alzheimer’s disease, including a placebo-treated noncarrier
cohort. Alzheimers Dement (N Y) 2018;4:150–60.
[5] Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker
test disclosures in neurodegenerative disease prevention trials.
Neurology 2015;84:1488–94.
[6] Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of
sporadic Alzheimer’s disease: lessons learned from clinical trials
and future directions. Lancet Neurol 2015;14:926–44.
[7] Wang J, Tan L, Yu JT. Prevention trials in Alzheimer’s disease: current
status and future perspectives. J Alzheimers Dis 2016;50:927–45.
[8] Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K,
Ayutyanont N, et al. Alzheimer’s prevention initiative: a plan to accel-
erate the evaluation of presymptomatic treatments. J Alzheimers Dis
2011;26:321–9.
[9] Lopez Lopez C, Caputo A, Liu F, Riviere ME, Rouzade-
Dominguez ML, Thomas RG, et al. The Alzheimer’s Prevention
Initiative Generation Program: evaluating CNP520 efficacy in the
prevention of Alzheimer’s disease. J Prev Alzheimers Dis 2017;
4:242–6.
[10] Lopez Lopez C, Tariot PN, Caputo A, Langbaum JB, Liu F,
Riviere ME, et al. The Alzheimer’s Prevention Initiative Generation
Program: study design of two randomized controlled trials for individ-
uals at risk for clinical onset of Alzheimer’s disease. Alzheimers De-
ment (N Y) 2019;5:216–27.
[11] Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB,
Rumbaugh M, et al. Genetic counseling and testing for Alzheimer dis-
ease: joint practice guidelines of the American College of Medical Ge-
netics and the National Society of Genetic Counselors. Genet Med
2011;13:597–605.
[12] National Institutes of Health, National Institute on Aging. Alzheimer’s
Disease Genetics Fact Sheet. National Institute on Aging: US Depart-
ment of Health and Human Services; 2015. Available at: https://www.
nia.nih.gov/health/alzheimers-disease-genetics-fact-sheet. Accessed
October 23, 2019.
[13] Genetic Testing Protocol for Huntington’s Disease Huntington’s Dis-
ease Society of America; 2016. Available at: http://hdsa.org/
wp-content/uploads/2015/02/HDSA-Gen-Testing-Protocol-for-HD.pdf.
Accessed October 23, 2019.
[14] Guidelines for the molecular genetics predictive test in Huntington’s
disease. International Huntington Association (IHA) and the World
Federation of Neurology (WFN) Research Group on Huntington’s
Chorea. Neurology 1994;44:1533–6.
[15] Romero LJ, Garry PJ, Schuyler M, Bennahum DA, Qualls C,
Ballinger L, et al. Emotional responses to APO E genotype disclosure
for Alzheimer disease. J Genet Couns 2005;14:141–50.
[16] Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ,
Brown T, et al. Disclosure of APOE genotype for risk of Alzheimer’s
disease. N Engl J Med 2009;361:245–54.[17] Roberts JS, Christensen KD, Green RC. Using Alzheimer’s disease as
a model for genetic risk disclosure: implications for personal geno-
mics. Clin Genet 2011;80:407–14.
[18] Christensen KD, Uhlmann WR, Roberts JS, Linnenbringer E,
Whitehouse PJ, Royal CDM, et al. A randomized controlled trial of
disclosing genetic risk information for Alzheimer disease via tele-
phone. Genet Med 2018;20:132–41.
[19] Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The
role of disease perceptions and results sharing in psychological adap-
tation after genetic susceptibility testing: the REVEAL Study. Eur J
Hum Genet 2010;18:1296–301.
[20] Roberts JS, Chen CA, Uhlmann WR, Green RC. Effectiveness of a
condensed protocol for disclosing APOE genotype and providing
risk education for Alzheimer disease. Genet Med 2012;14:742–8.
[21] Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ,
Royal CD, et al. A randomized noninferiority trial of condensed pro-
tocols for genetic risk disclosure of Alzheimer’s disease. Alzheimers
Dement 2015;11:1222–30.
[22] Harkins K, Sankar P, Sperling R, Grill JD, Green RC, Johnson KA,
et al. Development of a process to disclose amyloid imaging results
to cognitively normal older adult research participants. Alzheimers
Res Ther 2015;7:26.
[23] Milne R, Bunnik E, Diaz A, Richard E, Badger S, Gove D, et al. Per-
spectives on communicating biomarker-based assessments of Alz-
heimer’s disease to cognitively healthy individuals. J Alzheimers Dis
2018;62:487–98.
[24] Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent ev-
idence and development of a shorter version. Clin Gerontologist 1986;
5:165–73.
[25] Marteau TM, Bekker H. The development of a six-item short-form of
the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).
Br J Clin Psychol 1992;31:301–6.
[26] Tluczek A, Henriques JB, Brown RL. Support for the reliability and
validity of a six-item state anxiety scale derived from the State-Trait
Anxiety Inventory. J Nurs Meas 2009;17:19–28.
[27] Posner K, Brown G, Stanley B, Yershova K, Oquendo M, Currier G,
et al. The Columbia-Suicide Severity Rating Scale: initial validity
and internal consistency findings from three multisite studies with ad-
olescents and adults. Am J Psychiatry 2011;168:1266–77.
[28] Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, et al.
APOE-related risk ofmild cognitive impairment and dementia for preven-
tion trials: an analysis of four cohorts. PLoS Med 2017;14:e1002254.
[29] Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P,
Green RC. Estimating risk curves for first-degree relatives of patients
with Alzheimer’s disease: the REVEAL study. GenetMed 2004;6:192–6.
[30] 23andMe. Alzheimer’s Disease (APOE variants): Established
Research Report on 2 Reported Markers. Mountain View, CA:
23andMe; 2019.
[31] Kaphingst KA, McBride CM, Wade C, Alford SH, Reid R, Larson E,
et al. Patients’ understanding of and responses to multiplex genetic
susceptibility test results. Genet Med 2012;14:681.
[32] Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A,
Bonney G, et al. BRCA1 testing in families with hereditary breast-
ovarian cancer. A prospective study of patient decision making and
outcomes. JAMA 1996;275:1885–92.
[33] Kelly K, Leventhal H, Marvin M, Toppmeyer D, Baran J, Schwalb M.
Cancer genetics knowledge and beliefs and receipt of results in Ashke-
nazi Jewish individuals receiving counseling for BRCA1/2 mutations.
Cancer Control 2004;11:236–44.
[34] Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure
of subjective stress. Psychosom Med 1979;41:209–18.
[35] Stallard P, Velleman R, Baldwin S. Psychological screening of chil-
dren for post-traumatic stress disorder. J Child Psychol Psychiatry
1999;40:1075–82.
[36] Edwards L, Watson M, St James-Roberts I, Ashley S, Tilney C,
Brougham B, et al. Adolescent’s stress responses and psychological
C.M. Langlois et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 705-716716functioning when a parent has early breast cancer. Psychooncology
2008;17:1039–47.
[37] Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. “I
knowwhat you told me, but this is what I think:” perceived risk of Alz-
heimer disease among individuals who accurately recall their genetics-
based risk estimate. Genet Med 2010;12:219–27.
[38] LaRusse S, Roberts JS, Marteau TM, Katzen H, Linnenbringer EL,
Barber M, et al. Genetic susceptibility testing versus family history-
based risk assessment: impact on perceived risk of Alzheimer disease.
Genet Med 2005;7:48–53.
[39] Roberts JS. Anticipating response to predictive genetic testing for Alz-
heimer’s disease: a survey of first-degree relatives. Gerontologist
2000;40:43–52.
[40] Chung WW, Chen CA, Cupples LA, Roberts JS, Hiraki SC, Nair AK,
et al. A new scale measuring psychologic impact of genetic suscepti-
bility testing for Alzheimer disease. Alzheimer Dis Assoc Disord
2009;23:50–6.
[41] Pieterse AH, van Dulmen AM, Beemer FA, Bensing JM, AusemsMG.
Cancer genetic counseling: communication and counselees’ post-visit
satisfaction, cognitions, anxiety, and needs fulfillment. J Genet Couns
2007;16:85–96.
[42] Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN,
Schwartz MD, et al. A brief assessment of concerns associated with
genetic testing for cancer: the Multidimensional Impact of Cancer
Risk Assessment (MICRA) questionnaire. Health Psychol 2002;
21:564–72.
[43] DeMarco TA, Peshkin BN, Mars BD, Tercyak KP. Patient satisfaction
with cancer genetic counseling: a psychometric analysis of the
Genetic Counseling Satisfaction Scale. J Genet Couns 2004;
13:293–304.
[44] Dick PT, Filler R, Pavan A. Participant satisfaction and comfort with
multidisciplinary pediatric telemedicine consultations. J Pediatr Surg
1999;34:137–41. discussion 41–2.
[45] Alber J, Lee AKW, Menard W, Monast D, Salloway SP. Recruit-
ment of at-risk participants for clinical trials: a major paradigm
shift for Alzheimer’s disease prevention. J Prev Alzheimers Dis
2017;4:213–4.
[46] Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J,
Nusbaum R, Huang AT, et al. Randomized noninferiority trial of tele-phone versus in-person genetic counseling for hereditary breast and
ovarian cancer. J Clin Oncol 2014;32:618–26.
[47] Jenkins J, Calzone KA, Dimond E, Liewehr DJ, Steinberg SM,
Jourkiv O, et al. Randomized comparison of phone versus in-person
BRCA1/2 predisposition genetic test result disclosure counseling.
Genet Med 2007;9:487–95.
[48] Doughty Rice C, Ruschman JG, Martin LJ, Manders JB, Miller E.
Retrospective comparison of patient outcomes after in-person and tele-
phone results disclosure counseling for BRCA1/2 genetic testing. Fam
Cancer 2010;9:203–12.
[49] Klemp JR, O’Dea A, Chamberlain C, Fabian CJ. Patient satisfaction of
BRCA1/2 genetic testing by women at high risk for breast cancer
participating in a prevention trial. Fam Cancer 2005;4:279–84.
[50] Patrick-Miller L, Egleston BL, Daly M, Stevens E, Fetzer D,
Forman A, et al. Implementation and outcomes of telephone disclo-
sure of clinical BRCA1/2 test results. Patient Educ Couns 2013;
93:413–9.
[51] O’Shea R, Meany M, Carroll C, Cody N, Healy D, Green A, et al. Pre-
dictive genetic testing and alternatives to face to face results disclo-
sure: a retrospective review of patients preference for alternative
modes of BRCA 1 and 2 results disclosure in the Republic of Ireland.
J Genet Couns 2016;25:422–31.
[52] Bradbury AR, Egleston B, Patrick-Miller L, MCartyWood E, Jaeger J,
Reddy N, et al. Connect 4 APOE: A Randomized Study of Phone
versus Videoconference Delivery of APOE Genotype Disclosure in
the Generation Study 2016;12. . P324.
[53] Roberts JS, Gornick MC, Carere DA, Uhlmann WR, Ruffin MT,
Green RC. Direct-to-consumer genetic testing: user motivations, deci-
sion making, and perceived utility of results. Public Health Genomics
2017;20:36–45.
[54] Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying
therapies in Alzheimer’s disease: a primer, lessons learned, and a blue-
print for the future. J Alzheimers Dis 2018;64:S3–22.
[55] Chasioti D, Yan J, Nho K, Saykin AJ. Progress in polygenic composite
scores in Alzheimer’s and other complex diseases. Trends Genet 2019;
35:371–82.
[56] Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB,
Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of car-
diovascular risk. Circulation 2014;129:S49–73.
